IDH2 and glioblastoma: Glioblastomas, predominantly IDH-wild-type, exhibit aggressive molecular features including TERT promoter mutations, EGFR amplification, PTEN loss, and chromosome 7/10 alterations, leading to rapid growth and poor outcomes [15].